Sustained rise in antimicrobial resistance in India: ICMR study
The HinduA big chunk of patients in India may no longer benefit from carbapenem, a powerful antibiotic administered mainly in ICU settings to treat pneumonia and septicemia, as they have developed antimicrobial resistance to it, an ICMR study has found. The data analysis done between January 1 and December 31, 2021, pointed towards a sustained increase in drug-resistant pathogens, resulting in difficulty to treat certain infections with available medicines, senior Indian Council of Medical Research scientist Dr. Kamini Walia, who led the study, said. The resistance to broad-spectrum antibiotic carbapenem with respect to infections caused by Acinetobacter baumannii bacteria was recorded in 87.5% of the patients who were part of the study, limiting the availability of treatment options, the ICMR report said. "The ICMR AMR network has developed this over the last few years and now many labs are reporting antifungal susceptibility rates giving an idea on antifungal resistance rates.